Treatment with oral etoposide for childhood recurrent ependymomas

Alessandro Sandri, Maura Massimino, Luana Mastrodicasa, Nicola Sardi, Daniele Bertin, Maria Eleonora Basso, Liana Todisco, Alessandra Paglino, Giorgio Perilongo, Lorenzo Genitori, Laura Valentini, Umberto Ricardi, Lorenza Gandola, Felice Giangaspero, Enrico Madon

Research output: Contribution to journalArticlepeer-review


In this study the authors retrospectively evaluated the feasibility and effectiveness of prolonged oral etoposide therapy in children with recurrent ependymoma. Twelve ependymoma patients with documented recurrent or persistent disease were treated between May 1998 and October 2003. All patients were treated monthly with oral VP-16 administered at a dose of 50 mg/m2/d for 21 days, with a 7-day interval between cycles, for a planned minimum number of six cycles. Response (complete plus partial) after two cycles occurred in 5 of the 12 patients (41.6%). Response plus stable disease occurred in 10 of the 12 (83.3%), with a median duration of response or stable disease of 7 months (range 4-30). The median survival was 7 months; the 2-year progression-free survival was 16.7%. These results emphasize that oral etoposide is an attractive option for childhood recurrent ependymomas in terms of administration, tolerability, and neuroradiologic response.

Original languageEnglish
Pages (from-to)486-490
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Issue number9
Publication statusPublished - Oct 2005


  • Child
  • Ependymoma
  • Etoposide
  • Oral administration
  • Recurrence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology


Dive into the research topics of 'Treatment with oral etoposide for childhood recurrent ependymomas'. Together they form a unique fingerprint.

Cite this